Compare MASI & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MASI | RGEN |
|---|---|---|
| Founded | 1989 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 8.2B |
| IPO Year | 2007 | N/A |
| Metric | MASI | RGEN |
|---|---|---|
| Price | $138.48 | $157.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $188.80 | $170.90 |
| AVG Volume (30 Days) | ★ 765.7K | 696.6K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $2,182,000,000.00 | $707,890,000.00 |
| Revenue This Year | N/A | $17.84 |
| Revenue Next Year | $6.83 | $12.57 |
| P/E Ratio | ★ N/A | $6,185.26 |
| Revenue Growth | ★ 38.48 | 11.74 |
| 52 Week Low | $133.70 | $102.97 |
| 52 Week High | $194.88 | $182.52 |
| Indicator | MASI | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 47.50 |
| Support Level | $137.00 | $160.11 |
| Resistance Level | $142.70 | $165.02 |
| Average True Range (ATR) | 4.81 | 4.97 |
| MACD | -0.39 | -1.27 |
| Stochastic Oscillator | 19.81 | 7.12 |
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.